INTRODUCTION
In 1973, Ford 1 suggested that low maternal estrogen levels very early in pregnancy may be of clinical significance in determining the risk of fetal chromosomal abnormalities. This suggestion was based on the fact that gonadotrophins and estrogen levels are lower than average in the menstrual cycles of women beginning and ending their reproductive period, and that these women have a high incidence of chromosomal errors in their infants. Lejeune and Prieur 2 observed that among mothers 30 to 38 years old, there was an excess of pill-taking by mothers of trisomy 21 children, and that this excess was significant when the delay between the cessation of pill-taking and the conception of the child was 6 months or less. In 1982, Read 3 postulated that the natural decrease of estrogen production and an increase in the relative effect of endogenous androgens with age in women increase the quotient androgen/estrogen levels. This author considered that the increasing value of this quotient is a factor that predisposes to having a trisomy. He postulated that the contraceptive activity of the pill is associated with androgenic activity increasing the androgen/estrogen index, which had been associated with the production of Down syndrome in older mothers. Thus, if the androgenic activity produced by oral contraceptives (OCs) in young women acts near the time of conception, it may increase the risk for Down syndrome. This author also suggested that for older mothers with declining estrogen levels, the estrogen component of the contraceptive pill is of greater significance than the androgen component, while in younger mothers, with high estrogen levels, the androgenic effect is observed. Thus, he postulated a protective effect of the estrogens of OCs in older mothers.
Several studies 4 -7 have analyzed the relationship between OCs and Down syndrome, with negative results even in women using OCs and
OBJECTIVE:
There are some studies which analyzed the relationship between prenatal exposure to oral contraceptives ( OCs ) and Down syndrome, with conflicting results even in women using OCs and conceiving at different intervals after discontinuing the use of contraceptive pills. We analyzed the risk for Down syndrome in infants of women who become pregnant while taking OC.
STUDY DESIGN:
We used the data from the Spanish Collaborative Study of Congenital Malformations ( ECEMC ) . The ECEMC is a case -control study and surveillance system. For each malformed infant ( case ) , the next nonmalformed infant of the same sex born in the same hospital is selected as a control subject, from whom the collaborating physicians collected the same data as for the malformed infant. For the present study, we used two different approaches. First, the pair -matching analysis. Second, a casecontrol using the rest of the total of 17,183 controls from the ECEMC database with specified data on maternal use of OCs and maternal age. To control for maternal age, we used a logistic regression analysis.
RESULTS:
The results show an increased risk of 2.8 -fold for infants with Down syndrome in women younger than 35 years of age if the mother became pregnant while she was taking OCs. We did not observe this result for women older than 34 years of age.
CONCLUSION:
Our results showed that the risk for Down syndrome in infants born to mothers with less than 35 years of age ( as a group ) who became pregnant while taking OCs is near the risk for Down syndrome of mothers with more than 34 years of age, women who are candidates for prenatal diagnosis. Thus, based on our results, one may consider the possibility of offering prenatal diagnosis for Down syndrome to young women who became pregnant while they were taking OCs. 
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conceiving at different intervals after stopping OCs. Others have suggested that women who take OCs during the months just before conception, 2, 8 or get pregnant following OCs failure, 9 have an increased risk for Down syndrome.
In a previous analysis of the data from the Spanish Collaborative Study of Congenital Malformations (ECEMC), which was published in a booklet with limited distribution, 10 we observed an increased risk for Down syndrome in infants born to women who became pregnant while taking OCs. Here we present a more appropriate analysis of a larger sample of data from the ECEMC on the potential risk for Down syndrome if the mother became pregnant while she was taking OCs. We also analyze the effect of stopping use of OCs at different periods before conception, the shortest period being the next cycle after stopping the use of OCs (considered as 1 month).
MATERIALS AND METHODS
The study was based on data from the ECEMC. This is a hospitalbased case-control study and surveillance system with a methodology aimed not only at the surveillance of congenital anomalies, but also at investigating their characteristics, clusters of congenital malformations, and causes of congenital defects. The ECEMC is set up by two main groups: (1) the data-collecting group (peripheral group), which is made up of trained pediatricians, neonatologists, and gynecologists in over 76 collaborating hospitals throughout Spain who, being interested in the problem of congenital defects, collaborate with the ECEMC program and follow a unique strict methodology. They identify the cases and control infants and collect the data; (2) the coordinating group, located in Madrid, which is formed by a group of experts in dysmorphology, clinical genetics, biostatistics, epidemiology, and teratology who carry out the diagnosis of cases and perform the genetic and epidemiologic analyses. The methodology of the ECEMC can be summarized as follows.
Malformed Infants (Cases)
The collaborating physicians examine all the newborn infants in each participating hospital during the first 3 days of life to identify and describe those with major and/or minor/mild congenital defects (cases). They send the information to the coordinating group on a monthly basis. In many instances, photographs, karyotypes, imaging studies, pathology reports, and results of other studies are also available for review. The diagnosis of Down syndrome is based on 11 selected clinical features 11 and in more than 50% of the cases we have information about the karyotype; the karyotype-phenotype concordance being higher than 95%. Moreover, there was a total concordance in the phenotypic features between cases with karyotype and without karyotype. Thus, we consider that the cases without karyotype have more than 95% probability of having Down syndrome.
Control Children
For each malformed infant (case), the next non-malformed infant of the same sex born in the same hospital is selected as a control subject, from whom the collaborating physicians collected the same data as for the malformed infant. The controls were selected from the same population as the cases and were representative of those who, had they developed malformations, would have been selected as cases. For the present study, we used two types of controls: first, the matched controls; second, the rest of the total of 17,183 controls from the ECEMC database with specified data on maternal use of OCs and maternal age.
Exposure Variables and Information About Drugs
For each case and control, about 304 data items are collected. Within the first 3 days after delivery, the physicians (once they identify the case and control infants) interview the mothers of cases and control infants using defined protocols to gather information on family history, obstetrical data, and exposures during pregnancy such as acute and chronic maternal diseases, drugs, alcohol, and maternal occupation, among others. Thus, when the physician selects the case and control infants, he/she is blinded to the different prenatal exposures. There is a question in the protocols about the type of contraceptive methods used and the time after the mother abandons the contraceptive methods until she becomes pregnant. If the woman became pregnant while using a contraceptive pill, we consider this as time=0 months. The methodology of the ECEMC has been previously published. 12 -14 Between April 1976 and June 1998, the ECEMC surveyed a total of 1,527,579 liveborn infants, and 27,278 out of them were selected as cases because they had major and/or mild malformations and some minor anomalies detected during the first 3 days of life. Among the cases, 2056 were diagnosed as Down syndrome, 1506 of whom have specified data on OCs because the question on OCs was added in the protocols some time after April 1976. Among the 1506 cases, in 1277, OC was the last contraceptive method used. Thus, this is the population studied.
Definition of Exposed and Non-Exposed Infants
To study periconceptional exposure to OCs, we considered as exposed infants those cases whose mothers became pregnant during the use of contraceptive pills (month=0). However, to analyze the possible relationship with the use of OCs, we also studied those cases whose mothers stopped the contraceptive treatment at the following intervals before becoming pregnant: one month (which corresponds to the cycle immediately after stopping the pill), 2 months, 3 or more months. The non-exposed infants were those whose mothers did not use OCs.
Statistical Analysis
The analysis was done using the following approaches: first, the pairmatching analysis; second, a case-control study using the rest of the total controls of the ECEMC, using inference with 2Â2 tables; and third, different logistic regression models to control for maternal age.
RESULTS
The pair-matching analysis for young mothers ( <35 years of age) who became pregnant when they were taking OCs shows an odds ratio (OR) =8/1=8 (there were no pairs with both the case and the control exposed, eight pairs with the case exposed and the control unexposed, only one pair with the case unexposed and the control exposed, and 316 pairs with both the case and the control unexposed), with confidence limits of 1.07 and 332.33 (p=0.04). In the group of older mothers ( >34 years of age), we could not perform a pair-matching analysis because the sample size was very small. Table 1 depicts the sample size for young mothers using the rest of the total controls of the ECEMC, distributed in the different intervals during which their mothers stopped the contraceptive treatment. Table 2 presents the same data as Table 1 but for the group of mothers older than 34 years of age. The results show that while the risk for Down syndrome in younger mothers who became pregnant while they were taking OCs has a magnitude of 2.77-fold, in older mothers it is lower and statistically not significant. On the other hand, older mothers who stopped the use of OCs 1 month before becoming pregnant have a significantly lower risk for Down syndrome than those who did not use OCs (OR=0.31; 95% CI: 0.11-0.88; p=0.03). However, the CIs of all the ORs overlap.
To analyze if the type of OCs may influence the results, in those mothers with specified data, we calculated the OR for Down syndrome in women who became pregnant while taking OCs of high doses and this was OR=2.54 (CI: 0.56-11.43). The absence of significance is probably due to the sample size. We also calculated the OR for those women using OCs with low or medium doses, and the result was OR=2.88 (CI: 1.16-6.79). Thus, the magnitude of the OR does not change very much in relation to the doses of the different OCs. However, we cannot exclude the possibility that the risk could be lower for those OCs with very low doses.
We do not have the type of OC specified in all the cases and controls, but it is clear that those with high doses are decreasing along the time. However, for the rest of OC there are not clear tendencies along the time, although there are changes. To analyze if there is some relationship between the OC with high doses and Down syndrome, we have studied by years the proportion of cases of Down 
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Periconceptional Contraceptive Pills and Down Syndrome syndrome whose mothers became pregnant while taking OC, and we did not observe any decreasing tendency.
DISCUSSION
Previous studies analyzed the relationship between OCs and Down syndrome, with conflicting results. Some studies suggested that women who take OCs during the months just before conception, 2, 8 or get pregnant following OCs failure, 9 have an increased risk for Down syndrome. Other studies in women using OCs and conceiving at different intervals after discontinuing use of contraceptive pills have found no evidence of increased risk for Down syndrome. 4 -7,15 Recently, Yang et al. 16 also obtained negative results; but in the analysis, they considered in the same group those women who used OCs at any time during the period from 2 months before through 2 months after conception of the index case.
We have analyzed the risk for Down syndrome in women who became pregnant while taking OCs. Our results suggest an adjusted risk of 2.8-fold for Down syndrome in women younger than 35 years. This result is supported by the biological mechanisms postulated by different authors. In 1982, Read 3 postulated that the OCs activity is associated with the androgenic activity increasing the androgen/estrogen index, which is associated with the occurrence of Down syndrome in older mothers. Thus, if the androgenic activity produced by OCs in young women acts near the time of conception, it may increase the risk for Down syndrome. Our results on young women support the suggestion of Read.
3 However, more recently, Gaulden 17 proposed that hormonal imbalance might cause a less-thanoptimal microvasculature to develop around the maturating oocytes. The resulting decrease in the size of the perifollicular bed would reduce the volume of blood flow through the area and lead to an oxygen deficit in the egg. Moreover, Van Blerkom et al. 18 observed a relationship between perifollicular blood flow traits and the behavior of chromosomes within the developing oocytes. They found that oocytes from severely hypoxic follicles had high frequencies of abnormalities in chromosome organization on the metaphase spindle, possibly leading to an increased susceptibility to non-disjunction. A third possibility is that the increased risk for Down syndrome in infants of young mothers who became pregnant while they were taking OCs may be due to an alteration of the maternal capability to spontaneously abort trisomic embryos, leading to an increase of affected infants at birth.
The results of the analysis in older mothers do not show an increased risk for Down syndrome in women who became pregnant when they were taking OCs. Older mothers who stopped the use of OCs one or more months before becoming pregnant had OR for Down Syndrome less than unity, being this protective effect statistically significant only in those mothers who stopped OCs 1 month before conception. Although the OR for those women who became pregnant when they were taking OC is over the unity, is compatible with the hypothesis of a protective effect, since the lower confidence limit of this OR is below the unity and the confidence limits of all the other risks overlap. This suggestion of a protective effect for Down syndrome produced by OCs in older women is compatible with the proposal of Read. 3 He, considering that the natural decrease of estrogen production and the increase in the relative effect of endogenous androgens with age in women, increase the quotient androgen/estrogen levels, postulated that in older mothers with declining estrogen levels, the estrogen component of the contraceptive pill is of greater significance than the androgen component, leading to a protective effect. Taking this suggestion into account, and the fact that the maturation of the ovum proceeds in the presence of estrogens, the regulation of that quotient may prevent for Down syndrome. Thus, one may consider that the estrogenic effect of the OCs might decrease the ''natural'' high risk of these older mothers.
Consequently, only young mothers who became pregnant when they were taking OCs have an increased risk for Down syndrome. This result is concordance with that observed by Yang et al. 16 These authors, studying the effect of OCs and maternal smoking on the risk for Down syndrome, separated the mothers in younger than the age of 35 and older than the age of 34, and observed a positive association only in young mothers who used OCs and smoked. They concluded that the effect of environmental exposures may only be evident among younger mothers because in older women, the effect of time alone may be sufficient to disrupt meiotic events, and maternal age may obscure the effect of any added environmental exposure. Their results were observed only for maternal meiosis II -what is conceivable for environmental factors that act periconceptionally.
Limitations of our study include (1) small sample size, (2) recall bias, and (3) pregnancy termination in older mothers screened for trisomy 21. Decreased frequency of liveborn Down Syndrome infants in older mothers has been observed in Spain since 1985, when law permitting voluntary interruption of gestation for congenital defects was approved. 19, 20 We consider recall bias as not a likely explanation for the observed results because the physicians who identified the cases and selected the control infants were blinded to the contraceptive methods used by the mothers.
CONCLUSION
We observed that the risk for Down syndrome in mothers less than 35 years of age (as a group) who became pregnant while taking OCs increased by 2.8-fold. Thus, the frequency of Down syndrome in this group of women approximates the frequency of Down syndrome in older mothers. Offering prenatal diagnosis for Down syndrome to young women who became pregnant while they were taking OCs may be considered.
